Clinical trialNAActive not recruiting
Stereotactic MRI-guided On-table Adaptive Radiation Therapy (SMART) for Locally Advanced Pancreatic Cancer
Prospective Phase II Study of Stereotactic Magnetic Resonance Imaging (MRI) Guided On-table Adaptive Radiation Therapy (SMART) for Patients With Borderline or Inoperable Locally Advanced Pancreatic Cancer
- Outcome
- Ongoing
- Phase
- NA
- Status
- Active not recruiting
- Study type
- Interventional
- Start
- 1 January 2019
- Expected end
- January 2027
- Enrollment
- 133 participants
- Sites
- 13
- Primary outcomes
- Gastrointestinal toxicity assessed using Common Terminology Criteria for Adverse Events (CTCAE) v5
- Sponsor
- Industry
- Results posted
- No
- Last update
- 14 October 2022
These are registry fields. A trial card, with population, design, endpoints and result direction each tied to a quote, is not in the data yet.
Ask this document
Answers come only from this document’s own text, as highlighted quotes. If it doesn’t say, you are told so instead of given a guess. Only its metadata is loaded so far, so most questions will be declined.
Try
Papers 2
- Builds on itA Multi-Institutional Phase 2 Trial of Ablative 5-Fraction Stereotactic Magnetic Resonance-Guided On-Table Adaptive Rad… DOI 10.1016/j.ijrobp.2023.05.023↗
- BackgroundUsing adaptive magnetic resonance image-guided radiation therapy for treatment of inoperable pancreatic cancer. DOI 10.1002/cam4.2100↗